Drug intelligence / Profile preview

placebo + povidone iodine + chlorhexidine + nystatin

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Topical

Overview

This is a combination of four components used in clinical studies for oral conditions and wound management. The combination includes placebo (an inactive substance), povidone iodine (an antiseptic), chlorhexidine (an antibacterial agent), and nystatin (an antifungal medication). Studies have shown that when nystatin and chlorhexidine are combined, there may be interference with drug efficacy and increased degradation rates. This specific four-component combination appears to be used primarily in comparative clinical trials rather than as a standard therapeutic formulation.

Targets

Lipid A phosphate (Lipid A phosphate groups)Ergosterol

Beyond the preview

Go deeper on placebo + povidone iodine + chlorhexidine + nystatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo + povidone iodine + chlorhexidine + nystatin.

Explore the full profile